Associations Between Chronic Rhinosinusitis and Cancers: A Nationwide Population-Based Cohort Study
- Jeon, Yung Jin; Joo, Yeon-Hee; Cho, Hyun-Jin; Kim, Sang-Wook; Park, Bumjung; Choi, Hyo Geun
- Issue Date
- cancer; chronic rhinosinusitis; chronic inflammation; nasal polyp
- Journal Title
- Objective Chronic rhinosinusitis (CRS) is one of the most common chronic inflammatory diseases. The effect of chronic inflammation caused by CRS on the occurrence of various cancers has not been thoroughly evaluated. This study aimed to investigate the increased incidences of 10 types of cancers among CRS patients with/without nasal polyps (NP) using a national population-based database from the Korean Health Insurance Review and Assessment Service. Study Design A case-control cohort study. Methods We compared the prevalence of various comorbidities between CRS and control participants from a national cohort dataset of the Korean Health Insurance Review and Assessment Service. Methods CRS participants (n = 6,919) and non-CRS (n = 27,676) participants were selected from among the 514,866 participants from 2002 to 2015. A stratified Cox proportional hazards model was utilized to assess the hazard ratio (HR) of CRS for 10 types of cancers. Results A stratified Cox proportional hazard model demonstrated that the adjusted HR for hematologic malignancy was significantly higher in the CRS patients than in the controls regardless of the presence of NP (2.90 for total CRS; 2.15 for CRS with NP; 4.48 for CRS without NP). The HR for thyroid cancer was significantly higher in the CRS patients without NP but not in those with NP (1.50 for total CRS; 1.78 for CRS without NP). Conclusion This study showed that CRS participants had a significantly higher prevalence of hematologic malignancy and thyroid cancer. Level of Evidence 4 Laryngoscope, 2022
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.